振东制药：龙创基药业核心产品新药申请获受理

Core Viewpoint - The new drug application (NDA) for the core product "Vaginal Lactobacillus Dual Live Bacteria Capsules" by Guangdong Longchuang Biopharmaceutical Co., Ltd., in which the company holds a stake, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China [1] Group 1 - The product is a compound preparation consisting of Lactobacillus gasseri and Lactobacillus rhamnosus live bacteria [1] - The primary use of the product is for the restoration of vaginal flora and the treatment of bacterial vaginosis [1]